Single Fraction Lung SBRT
This webinar will review the history of lung SBRT, leading to single-fraction studies, and will discuss relevant research supporting the use of single-fraction SBRT. We will also consider whether single-fraction treatment is appropriate as a standard regimen.
Definitive Radiotherapy for Central or Ultra-Central Stage I Non-Small Cell Lung Cancer
This presentation will start by reviewing the relevant literature on the optimal dose-fractionation schemes for central and ultra-central lung tumors. We will delve into the recent guidelines produced by the International Stereotactic Radiosurgery Society and American Radium Society. Finally, we will discuss future directions in this space, often incorporating newer technologies like proton therapy and […]
Multi-technology Considerations for Early-stage Lung SBRT
Stereotactic body radiation therapy (SBRT) or stereotactic ablative radiotherapy (SABR) is increasingly being used in medically inoperable or high-risk patients diagnosed with early-stage non-small cell lung cancer. With the high-precision techniques required for stereotactic lung SBRT/SABR, a number of technology considerations must be considered in clinical practice. Although contouring principles, prescription doses, dose constraints, and […]
Lung SBRT in the Age of Immunotherapy
The presentation will cover the science, evidence, clinical benefits and safety of combining immunotherapy and stereotactic radiotherapy in the management of lung cancer.
SABR for Lung Cancer
The use of SABR for lung cancer is on the rise in both early stage and oligometastatic disease. The aim of this webinar is to discuss practical considerations to common challenges faced by the modern Radiation Oncologist within routine clinical practice.
When is SABR the Preferred Treatment in Lung Cancer?
The clinical use of SABR for early stage non-small cell lung cancer has increased considerable during the last decade. In this webinar, current and future indication for SABR in this disease will be discussed. Treatment of patients with a higher risk of toxicity due to tumor location or presence of interstitial lung disease will be […]
SBRT for Early Stage Lung Cancer
Stereotactic body radiotherapy (SBRT), is now a standard treatment option for patients with stage I non-small cell lung cancer or oligometastatic lung tumor who are medically inoperable or medically operable but refuse surgery. SBRT is extremely well tolerated, is an outpatient procedure, and has been reported to yield local tumor control rates exceeding 90%: it […]
SBRT as an Alternative for Surgery in Early Stage NSCLC
SBRT is now the standard treatment for patients with medically inoperable NSCLC. SABR is safe, effective and is associated with limited toxicity. These excellent results have led to the question whether SABR can also be used in medically operable NSCLC patients. In this webinar, after a short overview of the accomplishments of SABR in medically […]